Orthopedic Research Laboratory, Aarhus University Hospital, Aarhus N, Denmark.
Department of Biomedicine, Aarhus University, Aarhus C, Denmark.
Cartilage. 2021 Dec;13(2_suppl):254S-266S. doi: 10.1177/19476035211029707. Epub 2021 Jul 26.
This study evaluated the effects of mesenchymal stem cell-extracellular vesicles (MSC-EVs) on chondrocyte proliferation and on cartilage repair following bone marrow stimulation (BMS) of focal chondral defects of the knee.
Six adult Göttingen minipigs received 2 chondral defects in each knee. The pigs were randomized to treatment with either BMS combined with MSC-EVs or BMS combined with phosphate-buffered saline (PBS). Intraarticular injections MSC-EVs or PBS were performed immediately after closure of the surgical incisions, and at 2 and 4 weeks postoperatively. Repair was evaluated after 6 months with gross examination, histology, histomorphometry, immunohistochemistry, and micro-computed tomography (µCT) analysis of the trabecular bone beneath the defect.
Defects treated with MSC-EVs had more bone in the cartilage defect area than the PBS-treated defects (7.9% vs. 1.5%, = 0.02). Less than 1% of the repair tissue in both groups was hyaline cartilage. International Cartilage and Joint Preservation Society II histological scoring showed that defects treated with MSC-EVs scored lower on "matrix staining" (20.8 vs. 50.0, = 0.03), "cell morphology" (35.4 vs. 53.8, = 0.04), and "overall assessment" (30.8 vs. 52.9, = 0.03). Consistently, defects treated with MSC-EVs had lower collagen II and higher collagen I areal deposition. Defects treated with MSC-EVs had subchondral bone with significantly higher tissue mineral densities than PBS-treated defects (860 mg HA/cm vs. 838 mg HA/cm, = 0.02).
Intraarticular injections of MSC-EVs in conjunction with BMS led to osseous ingrowth that impaired optimal cartilage repair, while enhancing subchondral bone healing.
本研究评估了间充质干细胞-细胞外囊泡(MSC-EVs)对骨髓刺激(BMS)后膝部局灶性软骨缺损中软骨细胞增殖和软骨修复的影响。
6 只成年哥廷根小型猪的每只膝关节均接受 2 个软骨缺损。将猪随机分为 BMS 联合 MSC-EVs 治疗组和 BMS 联合磷酸盐缓冲液(PBS)治疗组。术后立即闭合手术切口,术后 2 周和 4 周时行关节内注射 MSC-EVs 或 PBS。6 个月后通过大体检查、组织学、组织形态计量学、免疫组织化学和缺损下小梁骨的微计算机断层扫描(µCT)分析评估修复情况。
与 PBS 治疗组相比,MSC-EVs 治疗组的软骨缺损区域有更多的骨(7.9%对 1.5%, = 0.02)。两组的修复组织中少于 1%为透明软骨。国际软骨和关节保存协会 II 组织学评分显示,MSC-EVs 治疗组在“基质染色”(20.8 对 50.0, = 0.03)、“细胞形态”(35.4 对 53.8, = 0.04)和“整体评估”(30.8 对 52.9, = 0.03)方面的评分较低。一致的是,MSC-EVs 治疗组的胶原 II 沉积面积较低,胶原 I 沉积面积较高。MSC-EVs 治疗组的软骨下骨的组织矿物质密度明显高于 PBS 治疗组(860 mg HA/cm 对 838 mg HA/cm, = 0.02)。
BMS 联合关节内注射 MSC-EVs 导致骨内生长,损害了最佳的软骨修复,同时增强了软骨下骨愈合。